Asianfin -- German pharmaceutical company BioNTech has announced its acquisition of Chinese biotech firm Biotheus to strengthen its oncology portfolio and secure global rights to the bispecific antibody candidate BNT327. BNT327, which has undergone clinical trials with cancer patients, was previously licensed to Biotheus for commercialization in the Greater China region. According to the terms of the deal, BioNTech will pay $800 million for full ownership of Biotheus, with additional milestone payments potentially reaching up to $150 million. The acquisition is expected to be finalized in the first quarter of 2025.